BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lpath, Inc. to Present at MDB Capital Group's Annual Bright Lights Conference on May 10, 2011


5/6/2011 9:04:15 AM

SAN DIEGO, CA--(Marketwire - May 05, 2011) - Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, has been invited to present at MDB Capital Group's Annual Bright Lights Conference. The conference will be held at the Le Parker Meridien Hotel in New York City on May 10-11, 2011.

Lpath's president and chief executive officer, Scott Pancoast, is scheduled to present on Tuesday, May 10, 2011 at 11:00 a.m. eastern time with one-on-one meetings held throughout the two days. He will discuss the company's progress, including status updates on the PEDigree and Nexus clinical trials, whereby the company's ocular drug candidate, iSONEP™, is being investigated in human proof-of-concept studies.

The presentation will be broadcast via webcast at http://wsw.com/webcast/mdb2/lptn.ob/. A replay link will also be available for 90 days following the live presentation in the investor relations section of the company's website at www.Lpath.com.

Lpath entered into an agreement with Pfizer (NYSE: PFE) in late 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP for any ocular indication. Pfizer and Lpath are collaborating closely on the two iSONEP clinical trials.

Pfizer also has a right of first refusal, which expires in late 2013, for Lpath's cancer drug candidate, ASONEP™. Lpath is planning to further investigate ASONEP in a Phase 2 trial involving renal cell carcinoma patients and perhaps in a second trial involving patients with prostate cancer or neuroblastoma.

Lpath was selected from MDB's 2011 group of "Best and Brightest" small-cap companies, a group that is advancing some of today's most innovative and market-leading intellectual property (IP). Lpath is one of the 40 public companies ranking in the 90th percentile for its respective technology leadership from more than 1,500 small-cap companies with granted U.S. patents, as rated by PatentVest, MDB's proprietary IP business-intelligence platform. Candidate companies have been scored, ranked, and analyzed on the basis of their rate of innovative change, as well as the novelty, quality, and industry impact of their patents.

For more information about the conference or to schedule a one-on-one meeting with Lpath management, contact your MDB Capital representative at 310-526-5004 or visit www.mdb.com/2011-bright-lights-conference.html.

About MDB Capital Group
MDB Capital Group LLC is an institutional research and investment banking firm that focuses exclusively on companies that possess market-changing, disruptive intellectual property. For more information, visit www.mdb.com.

About Lpath
San Diego-based Lpath, a therapeutic antibody company, is the category leader in lipidomics-based therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates, two of which -- iSONEP for wet AMD and ASONEP for cancer -- have completed Phase 1 clinical trials. Lpath entered into an agreement with Pfizer (NYSE: PFE) in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP. For more information, visit www.Lpath.com.


Lpath, Inc.
Scott R. Pancoast
President & CEO
858-678-0800 x104
Email Contact

Lpath Investor Relations
Liolios Group, Inc.
(949) 574-3860
Ron Both:
Email Contact
Geoffrey Plank:
Email Contact
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES